Robert Clarke

Company: Kinaset Therapeutics

Job title: Chief Executive Officer & Co-Founder

Seminars:

Overview of JAK Inhibitor Inhaled Formulation 11:15 am

Cataloguing autoimmune diseases where JAK inhalation may be sensible Considering toxicity and potential for off-target effects with inhaled JAKs Evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of a novel potent pan-JAK inhaled as a dry powderRead more

day: Day One

PANEL DISCUSSION – The Road Ahead: Topicals vs Orals vs Alternative Delivery Methods 9:30 am

Exploring the JAK inhibitor drug development landscape and weighing the merit of pursuing topical vs oral vs alternative application Considering the cost concerns and systemic effects associated with oral and injectable delivery systems whilst discussing the small potential for off-target effects in topical creams Discussing the need to equate disease severity and quality of life…Read more

day: Day One